United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer's Cibinqo snagged an approval in Japan to treat patients with eczema.

Pfizer Just Scored Another Key Regulatory Approval

Johnson & Johnson

Moderna

J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.

J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study Finds

The NIH study on “mixing and matching” Covid vaccines included more than 450 adults who have received one of the three regimens currently available in the United States: J&J's, Moderna's or Pfizer's.

J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggests

Someone with a lot of money to spend (and possibly insider knowledge) has taken a bullish stance on Pfizer(NYSE:PFE). And retail traders should know.

Pfizer Whale Trades Spotted

Pfizer is expanding beyond its coronavirus vaccine.

Can Pfizer Beat Moderna in mRNA Vaccines?

Costco

Delta Air Lines

FedEx

JPMorgan Chase & Co

NIKE

After a down day yesterday, we see the Dow +30 points, the S&P 500 +3 points and the Nasdaq +33.

Pre-Markets Back to Green Ahead of Economic & Earnings Data

Rare heart inflammation issues with Moderna's vaccine could work to Pfizer's advantage -- but only slightly.

How Could Pfizer Be Affected by Moderna's Vaccine Safety Issues?

Pfizer (PFE) closed at $42.06 in the latest trading session, marking a -0.92% move from the prior day.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pfizer (PFE) is a Top-Ranked Growth Stock: Should You Buy?

Pfizer is one of the key leaders in the US Pharmaceutical industry. The company has delivered huge success with its COVID-19 vaccine.

Is Pfizer Stock A Buy Or Sell After Booster Shot Authorization?

Pfizer might not be far behind Merck in launching a COVID-19 pill.

4 Key Things Investors Should Know About Pfizer's Experimental COVID-19 Pill

DoorDash

Match Group

Netflix

Pinterest

Teladoc

Zoom Video

These seven top stocks are among my top picks for investors seeking exposure to companies with the ability to ride out market turmoil. The post 7 Top Stocks That Held Up Well During This Recent Market Bloodbath appeared first on InvestorPlace.

7 Top Stocks That Held Up Well During This Recent Market Bloodbath

This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.

Better Investment: Pfizer or Moderna

Pfizer is now set to receive money from its top rival in the pneumococcal vaccine market.

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine

Merck

The companies will vie for leadership in this billion-dollar market.

Better Bet on COVID Pills: Merck or Pfizer?

Pharmaceutical giant Pfizer recently reminded employees that they could face disciplinary action if they do not comply with a companywide vaccine mandate ahead of an upcoming deadline.

Pfizer tells workers to be vaccinated by Nov. 15 or face disciplinary action

Freeport-McMoRan

Procter & Gamble

Here's why long-term investors seeking defensive stocks to buy right now may want to consider these top seven options right now. The post 7 Defensive Stocks to Buy and Forget About In Times of Volatility appeared first on InvestorPlace.

7 Defensive Stocks to Buy and Forget About In Times of Volatility

Pfizer's leadership in the COVID arena has made the stock a darling for investors during the Pandemic.

News From New Zealand Makes Pfizer A Buy For 2022 And Beyond

Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)

Right now, Pfizer has emergency authorization for use in kids as young as 12 in the US. It's the only drug maker with that status.

Pfizer asks FDA to authorize its COVID-19 vaccine for kids 5 and up

BioNTech SE

Shares of Pfizer Inc. PFE, -0.71% were up 0.1% in premarket trading on Thursday after the company and BioNTech SE BNTX, -5.59% announced they submitted an application for emergency use authorization for their COVID-19 vaccine in children between the ages of 5 and 11 years old. The Food and Drug Administration will review the safety and efficacy of the vaccine before deciding whether to authorize the shot for this age group.

Pfizer, BioNTech file for FDA authorization for their COVID-19 vaccine in children

Pfizer said Thursday it asked the FDA to authorize its Covid-19 vaccine with BioNTech for kids ages 5 to 11.

Pfizer asks FDA to authorize Covid vaccine for kids ages 5 to 11

Two studies have confirmed that the protection against coronavirus infection provided by the COVID-19 vaccine developed by Pfizer Inc and BioNTech falls after a few months, although the vaccine's protection against hospitalisation and death remains strong. The studies, from Israel and from Qatar, were published in the New England Journal of Medicine.

COVID-19: Pfizer vaccine protection could drop to 20% after 5 months, study shows

AstraZeneca

Novavax

It'll likely push the revenue of vaccine victors even further.

What Do Mix-and-Match Doses Mean for Vaccine Stocks?

Anthem

Catalent

CVS Health

Medtronic

UnitedHealth Group

Healthcare stocks could take over from energy stocks as top dog during this defensive cycle as yields move higher and tech stocks lose value. The post 7 Healthcare Stocks to Add to Your Portfolio appeared first on InvestorPlace.

News for Pfizer Stock (PFE)